萬邦德(002082.SZ)：萬邦德製藥前11月淨利升24.79% 年度扣非淨利預增20.78%
格隆匯12月12日丨萬邦德(002082.SZ)公佈，2019年1-11月，萬邦德製藥集團股份有限公司(以下簡稱“萬邦德製藥”)實現營業收入為7.78億元，佔2019年度營業收入預測值的比例為88.05%，實現扣非後歸屬於母公司淨利潤為1.66億元，佔2019年度淨利潤預測值的比例為90.02%，預計2019年度能夠較好的實現盈利預測。
2019年1-11月，萬邦德製藥營業收入為7.78億元，同比增長27.17%；營業利潤為2.21億元，同比增長25.55%；歸屬於母公司所有者淨利潤為1.81億元，同比增長24.79%，主要系標的公司憑藉銀杏葉滴丸等產品競爭優勢、銷售渠道優勢，實現主要產品產銷量的增長，銀杏葉滴丸、鹽酸溴己新片、聯苯雙酯滴丸、聯苯雙酯、其他產品銷售收入較2018年同期分別增長37.36%、22.32%、37.97%、19.72%、44.83%，均高於2019年盈利預測上述產品銷售收入的增長，帶動營業收入的增長。
2019年度，萬邦德製藥營業收入預測數為8.84億元，較2018年度增長20.02%，扣非後歸屬於母公司淨利潤預測數為1.85億元，較2018年度增長20.78%，而2019年1-11月萬邦德製藥營業收入同比增長27.17%，扣非後歸屬於母公司淨利潤同比增長22.60%，2019年1-11月經營業績增長率高於盈利預測增長率；同時，2019年1-11月，銀杏葉滴丸、聯苯雙酯滴丸、其他產品的銷售收入增長率也高於盈利預測的增長率，上述2019年1-11月經營指標較上年同期增長率高於預測期增長率，為2019年度盈利預測的實現提供保障。同時，截至2019年11月末，新產品間苯三酚注射液、石杉鹼甲注射液實現銷售收入合計為4800多萬元，為未來業績的持續增長提供新的增長點。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
